

References

R-5043

1. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet*. May 18 2002;359(9319):1734-1739. PMID 12049862.
2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology*. May 2002;35(5):1164-1171. PMID 11981766.
3. Tao R, Li X, Ran R, et al. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. *Oncotarget*. Jan 17 2017;8(3):5460-5473. PMID 27705924.
4. Ludwig JM, Zhang D, Xing M, et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. *Eur Radiol*. May 2017;27(5):2031-2041. PMID 27562480.
5. Lobo L, Yakoub D, Picado O, et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. *Cardiovasc Intervent Radiol*. Nov 2016;39(11):1580- 1588. PMID 27586657.
6. Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. *World J Hepatol*. Jun 28 2016;8(18):770-778. PMID 27366304.
7. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. *Eur Radiol*. Nov 2009;19(4):951-959. PMID 18989675.
8. Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. *Liver Int*. Jun 2015;35(6):1715-1721. PMID 25443863.
9. Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. *Cardiovasc Intervent Radiol*. Apr 2015;38(2):352-360. PMID 25373796.
10. Padia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. *J Vasc Interv Radiol*. Jun 2017;28(6):777-785 e771. PMID 28365172.

11. Soydal C, Arslan MF, Kucuk ON, et al. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. *Nucl Med Commun*. Jun 2016;37(6):646-649. PMID 26905317.
12. Oladeru OT, Miccio JA, Yang J, et al. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. *J Gastrointest Oncol*. Jun 2016;7(3):433-440. PMID 27284477.
13. El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? *Liver Int*. Feb 2015;35(2):627-635. PMID 25040497.
14. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver Int*. Mar 2015;35(3):1036-1047. PMID 24750853.
15. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two- cohort study. *Cancer*. Mar 1 2010;116(5):1305-1314. PMID 20066715.
16. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. *Hepatology*. Jan 2018;67(1):381-400. PMID 28859222.
17. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology*. Dec 2016;151(6):1155- 1163 e1152. PMID 27575820.
18. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. *J Hepatol*. Aug 2014;61(2):309-317. PMID 24681342.
19. Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single- institution experience. *J Vasc Interv Radiol*. Nov 2013;24(11):1632-1638. PMID 24160821.
20. Ramanathan R, Sharma A, Lee DD, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. *Transplantation*. Jul 15 2014;98(1):100-106. PMID 24503764.
21. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant*. Aug 2009;9(8):1920-1928. PMID 19552767.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 2.2018.

https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
Accessed June 27, 2018.

23. Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis. *Eur J Surg Oncol*. Jan 2015;41(1):120-127. PMID 25449754.
24. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. *J Vasc Interv Radiol*. Aug 2013;24(8):1227-1234. PMID 23602420.
25. Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovasc Intervent Radiol*. Feb 2012;35(1):105-116. PMID 21431970.
26. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. *Ann Surg Oncol*. Feb 2010;17(2):484-491. PMID 19876691.
27. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. *J Surg Oncol*. Feb 2015;111(2):213-220. PMID 25176325.
28. Chan LS, Sze DY, Poultsides GA, et al. Yttrium-90 radioembolization for unresectable combined hepatocellular- cholangiocarcinoma. *Cardiovasc Intervent Radiol*. Sep 2017;40(9):1383-1391. PMID 28432387.
29. Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. *J Cancer Res Clin Oncol*. Mar 2017;143(3):481-489. PMID 27826686.
30. Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. *Br J Cancer*. Jul 26 2016;115(3):297-302. PMID 27336601.
31. Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. *Ann Surg Oncol*. Sep 2015;22(9):3102-3108. PMID 25623598.
32. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. *Eur J Nucl Med Mol Imaging*. Jun 2011;38(6):1037- 1045. PMID 21308371.
33. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium- 90 microspheres: results from a pilot study. *Cancer*. Oct 15 2008;113(8):2119-2128. PMID 18759346.

34. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer*. Sep 1 2008;113(5):921-929. PMID 18618495.
35. Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. *J Nucl Med*. Sep 2014;55(9):1404-1410. PMID 25012459.
36. Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. *Pancreas*. Mar 2014;43(2):219-225. PMID 24518499.
37. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg*. Jun 2008;247(6):1029-1035. PMID 18520231.
38. Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *Br J Surg*. Apr 2010;97(4):537-543. PMID 20205229.
39. Kennedy AS, Dezar WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol*. Jun 2008;31(3):271-279. PMID 18525307.
40. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. *Int J Radiat Oncol Biol Phys*. Jul 1 2012;83(3):887-894. PMID 22137020.
41. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovasc Intervent Radiol*. Apr 2012;35(2):334-342. PMID 21847708.
42. Peker A, Cicek O, Soydal C, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. *Diagn Interv Radiol*. Jan-Feb 2015;21(1):54-59. PMID 25430526.
43. Jia Z, Paz-Fumagalli R, Frey G, et al. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. *J Gastroenterol Hepatol*. Sep 2017;32(9):1617-1623. PMID 28132407.
44. Fan KY, Wild AT, Halappa VG, et al. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. *Contemp Clin Trials*. Sep 2016;50:143-149. PMID 27520932.
45. Tice J. Selective internal radiation therapy or radioembolization for inoperable liver metastases from colorectal cancer San Francisco, CA: California Technology Assessment Forum; 2010.

46. Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. *J Cancer Res Clin Oncol*. Apr 2014;140(4):537-547. PMID 24318568.
47. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol*. Dec 2001;12(12):1711-1720. PMID 11843249.
48. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*. Aug 10 2010;28(23):3687-3694. PMID 20567019.
49. Rosenbaum CE, Verkooijen HM, Lam MG, et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. *J Nucl Med*. Nov 2013;54(11):1890-1895. PMID 24071510.
50. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol*. Nov 1 2004;88(2):78-85. PMID 15499601.
51. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. *Cochrane Database Syst Rev*. Oct 07 2009(4):CD007045. PMID 19821394.
52. Van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. *J Clin Oncol*. May 20 2016;34(15):1723- 1731. PMID 26903575.
53. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology*. Jan 2010;138(1):52-64. PMID 19766639.
54. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovasc Intervent Radiol*. Oct 2012;35(5):1066-1073. PMID 21800231.
55. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed June 27, 2018.

56. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer J*. Mar-Apr 2010;16(2):163-175. PMID 20404614.
57. Smits ML, Prince JF, Rosenbaum CE, et al. Intra-arterial radioembolization of breast cancer liver metastases: a structured review. *Eur J Pharmacol*. Jun 5 2013;709(1-3):37-42. PMID 23545356.
58. Pieper CC, Meyer C, Wilhelm KE, et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases—a single-center experience. *J Vasc Interv Radiol*. Sep 2016;27(9):1305-1315. PMID 27461588.
59. Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. *J Vasc Interv Radiol*. Oct 2014;25(10):1523-1532, 1532 e1521-1522. PMID 25156827.
60. Saxena A, Kapoor J, Meteling B, et al. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. *Ann Surg Oncol*. Apr 2014;21(4):1296-1303. PMID 24337647.
61. Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. *Eur Radiol*. Jul 2013;23(1):182-189. PMID 22836160.
62. Haug AR, Tiega Donfack BP, Trumm C, et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. *J Nucl Med*. Feb 2012;53(3):371-377. PMID 22331219.
63. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. *J Vasc Interv Radiol*. May 2008;19(5):683-690. PMID 18440456.
64. Bangash AK, Atassi B, Kaklamani V, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. *J Vasc Interv Radiol*. May 2007;18(5):621-628. PMID 17494843.
65. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. *Int J Radiat Oncol Biol Phys*. Nov 1 2007;69(3):800-804. PMID 17524567.
66. Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal Yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy: safety and efficacy cohort study. *Am J Clin Oncol*. Feb 2017;40(1):27-34. PMID 25089529.
67. Eldredge-Hindy H, Ohri N, Anne PR, et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. *Am J Clin Oncol*. Apr 2016;39(2):189-195. PMID 24441583.

68. Gonsalves CF, Eschelmann DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. *AJR Am J Roentgenol*. Feb 2011;196(2):468-473. PMID 21257902.
69. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. *Cancer Invest*. Jul 2009;27(6):682-690. PMID 19219675.
70. Klingenstein A, Haug AR, Zech CJ, et al. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. *Cardiovasc Intervent Radiol*. Feb 2013;36(1):158-165. PMID 22526099.
71. Piduru SM, Schuster DM, Barron BJ, et al. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *J Vasc Interv Radiol*. Jul 2012;23(7):943-948. PMID 22609292.
72. Michl M, Haug AR, Jakobs TF, et al. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. *Oncology*. Jan 2014;86(1):24-32. PMID 24401529.
73. Miller MD, Sze DY, Padia SA, et al. Response and overall survival for yttrium-90 radioembolization of hepatic sarcoma: a multicenter retrospective study. *J Vasc Interv Radiol*. Jun 2018;29(6):867-873. PMID 29724518.
74. National Comprehensive Cancer Network. Hapatobiliary carcinoma. Version 2.2019. Accessed May 21, 2019. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
75. National Comprehensive Cancer Network. Neuroendocrine tumors. Version 1.2019. Accessed May 22, 2019. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.
76. National Comprehensive Cancer Network. Colon Cancer. Version 2.2019. Accessed May 22, 2019. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.